Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

FDA approves Novartis’ Vijoice for to treat rare PROS genetic diseases

By Sean Whooley | April 8, 2022

Novartis logoNovartis announced that it received FDA approval for its Vijoice (alpelisib) PIK3CA-Related Overgrowth Spectrum (PROS) treatment.

Basel, Switzerland-based Novartis said in a news release that Vijoice is the first FDA-approved treatment for PROS, a spectrum of rare conditions characterized by overgrowth in blood vessel anomalies.

FDA approval followed real-world evidence from the EPIK-P1 retrospective chart review study demonstrating the success of Vijoice in reducing target lesion volume and the improvement in PROS-related symptoms and manifestations. At week 24, 27% of patients (10/37) achieved a confirmed a response to treatment, defined as 20% or greater reduction in the sum of PROS target lesion volume.

Nearly three-quarters of patients (74%) with imaging at baseline and week 24 showed some reduction in target lesion volume, while patients reported improvements in pain (90%), fatigue (76%), vascular malformation (79%), limb asymmetry (69%) and disseminated intravascular coagulation (55%).

The most common adverse events in the trial were diarrhea (16%), stomatitis (16%) and hyperglycemia (12%). The most common grade 3/4 adverse event as cellulitis (4%), with one case considered to be treatment-related.

“The approval of Vijoice marks a turning point for patients who, until now, have not had an approved therapy to specifically address their disease,” Novartis Innovative Medicines U.S. President Victor Bulto said in the release. “We are grateful to the physicians, patients and families who participated in the EPIK-P1 trial. We are continuing to invest in studies to advance the scientific understanding of PROS conditions and to understand the full potential of Vijoice.”

Tell Us What You Think! Cancel reply

Related Articles Read More >

Biogen logo
Biogen is scaling back space outside Boston
Fresenius Kabi
Fresenius Kabi plans to add 2D barcodes to its pharmaceutical portfolio
Dollars for drugs
Democrats’ drug pricing plan attracts pushback from Republicans
GBT/Pfizer
Pfizer to scoop up Global Blood Therapeutics for $5.4 billion 

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards